Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
Join expert faculty to ensure you’re appropriately managing the care of your patients with ASCVD.
Live
Meeting
3.00 available credits
Information
April 04, 2022
05:45 PM - 09:30 PM CDT
Marriott Marquis Houston
1777 Walker Street, Houston, Texas, United States
Share
Share
Share this program on:
Choose a format
Details
Presenters
Related
Comments
Program Schedule*
5:45 PM–6:30 PM
Registration and Dinner
6:30 PM–6:35 PM
Welcome, Introductions, Program Overview
Christie Ballantyne, MD
Program Chair6:35 PM–6:45 PM
Burden of Heart Disease Today
Christie Ballantyne, MD6:45 PM–7:05 PM
Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
Gregory Pokrywka, MD7:05 PM–7:30 PM
REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
Karol Watson, MD7:30 PM–7:45 PM
Panel Discussion
All faculty7:45 PM–8:00 PM
Break
8:00 PM–8:15 PM
Recent Evidence from REDUCE-IT Sub-studies
Karol Watson, MD8:15 PM–8:35 PM
Differential Biological Effects of Omega-3 Fatty Acids
Gregory Pokrywka, MD8:35 PM–8:55 PM
Role of Pharmacist in Establishing Lipid Intervention
Joseph Saseen, PharmD, BCPS, BCACP8:55 PM–9:10 PM
Panel Discussion
All Faculty9:10 PM–9:25 PM
Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
All Faculty9:25 PM–9:30 pm
Closing Comments, Adjourn
Karol Watson, MD*Subject to change
Click Here to Download Slide Presentation
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Christie M. Ballantyne, MD
Chief, Sections of Cardiology and Cardiovascular Research
Professor and Vice Chair of Research
J.S. Abercrombie Chair, Atherosclerosis & Lipoprotein Research
Department of Medicine
Director, Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX
Research: Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, lonis, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic.
Consulting Fees: Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, lllumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-SynthelaboFaculty:
Gregory S. Pokrywka, MD, FACP, FNLA, FASPC, NCMP
Director: Baltimore Lipid Center
Assistant Professor
Johns Hopkins University School of Medicine
Baltimore, MD
Commercial Interest Speakers Bureau: Amarin, Amgen, EsperionJoseph Saseen, PharmD
Professor, Departments of Clinical Pharmacy and Family Medicine
Vice Chair, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Aurora, CO
No relationship reportedKarol Watson, MD, PhD
Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women's Heart Health Program
David Geffen School of Medicine at UCLA
Los Angeles, CA
Consulting Fees: Amarin, Amgen, Boehringer-Ingelheim, Lilly, Esperion, Novo NordiskReviewers/Content Planners/Authors:
- Sean T. Barrett has nothing to disclose
- Cindy Davidson has nothing to disclose.
- Libby Lurwick has nothing to disclose
- Kate Nagele has nothing to disclose.
- Mario Trucillo, PhD, MS has nothing to disclose.
- Kathy Wickman has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
- Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
- Identify barriers to the implementation of effective, long-term management of ASCVD
Target Audience
This activity is designed to meet the educational needs of primary care physicians and community pharmacists.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.
Presenters
Related
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
Show more
Details
Presenters
Related
Comments
Overview
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Program Schedule*
5:45 PM–6:30 PM
Registration and Dinner
6:30 PM–6:35 PM
Welcome, Introductions, Program Overview
Christie Ballantyne, MD
Program Chair6:35 PM–6:45 PM
Burden of Heart Disease Today
Christie Ballantyne, MD6:45 PM–7:05 PM
Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
Gregory Pokrywka, MD7:05 PM–7:30 PM
REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
Karol Watson, MD7:30 PM–7:45 PM
Panel Discussion
All faculty7:45 PM–8:00 PM
Break
8:00 PM–8:15 PM
Recent Evidence from REDUCE-IT Sub-studies
Karol Watson, MD8:15 PM–8:35 PM
Differential Biological Effects of Omega-3 Fatty Acids
Gregory Pokrywka, MD8:35 PM–8:55 PM
Role of Pharmacist in Establishing Lipid Intervention
Joseph Saseen, PharmD, BCPS, BCACP8:55 PM–9:10 PM
Panel Discussion
All Faculty9:10 PM–9:25 PM
Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
All Faculty9:25 PM–9:30 pm
Closing Comments, Adjourn
Karol Watson, MD*Subject to change
Click Here to Download Slide Presentation
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Christie M. Ballantyne, MD
Chief, Sections of Cardiology and Cardiovascular Research
Professor and Vice Chair of Research
J.S. Abercrombie Chair, Atherosclerosis & Lipoprotein Research
Department of Medicine
Director, Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX
Research: Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, lonis, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic.
Consulting Fees: Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, lllumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-SynthelaboFaculty:
Gregory S. Pokrywka, MD, FACP, FNLA, FASPC, NCMP
Director: Baltimore Lipid Center
Assistant Professor
Johns Hopkins University School of Medicine
Baltimore, MD
Commercial Interest Speakers Bureau: Amarin, Amgen, EsperionJoseph Saseen, PharmD
Professor, Departments of Clinical Pharmacy and Family Medicine
Vice Chair, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Aurora, CO
No relationship reportedKarol Watson, MD, PhD
Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women's Heart Health Program
David Geffen School of Medicine at UCLA
Los Angeles, CA
Consulting Fees: Amarin, Amgen, Boehringer-Ingelheim, Lilly, Esperion, Novo NordiskReviewers/Content Planners/Authors:
- Sean T. Barrett has nothing to disclose
- Cindy Davidson has nothing to disclose.
- Libby Lurwick has nothing to disclose
- Kate Nagele has nothing to disclose.
- Mario Trucillo, PhD, MS has nothing to disclose.
- Kathy Wickman has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
- Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
- Identify barriers to the implementation of effective, long-term management of ASCVD
Target Audience
This activity is designed to meet the educational needs of primary care physicians and community pharmacists.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.
Presenters
Related
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
Show more
Facebook Comments